Doctor taking notes

Resources

Publications

Jun 2021
Safety and Pharmacokinetics of DUR-928 in Hepatic Function Impaired Subjects 
Jaymin Shah, Katherine Pozo, Deborah Scott, and WeiQi Lin | The European Association for the Study of the Liver (EASL) International Liver Congress
Jun 2021
Efficacy Signals of 4-Week Oral DUR-928 in NASH Subjects
Eric Lawitz, Terek Hassanein, Douglas Denham, Michael Waters, Brian Borg, Gwenaelle Mille, Deborah Scott, Andy Miksztal, John Culwell, Dave Ellis, Jim Brown, and WeiQi Lin | The European Association for the Study of the Liver (EASL) International Liver Congress
Jan 2021
25-Hydroxycholesterol 3-sulfate is an endogenous ligand of DNA methyltransferases in hepatocytes 
Yaping Wang, Weiqi Lin, James E. Brown, Lanming Chen, Williams M. Pandak, Phillip B. Hylemon, and Shunlin Ren | Journal of Lipid Research
Aug 2020
Pharmacokinetics of DUR-928 in Alcoholic Hepatitis Patients – A Phase 2a Study
Jaymin Shah, Christina Blevins, Deborah Scott, Andy Miksztal, and WeiQi Lin | The European Association for the Study of the Liver (EASL)
Nov 2019
Safety and Efficacy of DUR-928: A Potential New Therapy for Acute Alcoholic Hepatitis 
Tarek Hassanein, Lance L Stein, Steven L Flamm, Paul Martin, Matthew C. Cave, Christina Blevins, Deborah Scott, William Krebs, and WeiQi Lin | American Association for the Study of Liver Diseases (AASLD) The Liver Meeting

Factsheets

See the resources included here for more information and resources from DURECT.

Scroll to Top